Company Overview and News
I look at what happens to the stock price if gold goes to both $800 and $2,000.
Newmont Mining Corporation (NEM - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $29.87 to $31.56 in the past one-month time frame.
NDMWF NEM NAK
De Grey Mining Ltd (ASX:DEG) will begin testing what could be more conglomerate gold nuggets from its Pilbara Gold Project 80 kilometres southwest of Port Hedland.
DEG PIO KGI NSRPF NEM KGI.DB.A KGI.DB NVO PIONF KL
Diversity in mining starts at the top according to Newmont Mining chief executive officer Gary Goldberg ahead of his appearance at the 5th annual International Mining and Resources Conference (IMARC) taking place in Melbourne from October 29 to November 1.
Barrick Gold Corporation (ABX - Free Report) announced that it has inked an agreement with Randgold Resources Limited for a recommended share-for-share merger. The merger is expected to close by the first quarter of 2019, which is subject to approval by the companies’ shareholders, regulatory approvals and other customary closing conditions. Per the terms, each shareholder of Randgold will receive 6.
HUN ABX NEM RGORF AEM GOLD GG RRS ABX GOLD
In an effort to become a more efficient gold miner while also remaining the world’s biggest, Barrick Gold (NYSE:ABX) announced Monday that it is buying Randgold Resources (NASDAQ:GOLD) for $6 billion in ABX stock. For every share of GOLD stock held, Rangold shareholders will receive 6.128 new shares of ABX stock.
ABX NEM RGORF GOLD GG RRS ABX GOLD
LONDON (Reuters) - Canada’s Barrick Gold Corp has agreed to buy Randgold Resources Ltd in an all-stock deal valuing the Africa-focused miner at $6.5 billion, to create the world’s largest gold producer in an industry under investor pressure to put capital to good use.
ABX NEM RGORF ABGLF GOLD RRS GOLD ABGLY ACA MS ABX
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to NEM / Newmont Mining Corp. on message board site Silicon Investor.
as of ET